Serum quantitative proteomic analysis reveals potential zinc-associated biomarkers for nonbacterial prostatitis - Abstract

BACKGROUND: Prostatitis is one of the most common urological problems afflicting adult men.

The etiology and pathogenesis of nonbacterial prostatitis, which accounts for 90-95% of cases, is largely unknown. As serum proteins often indicate the overall pathologic status of patients, we hypothesized that protein biomarkers of prostatitis might be identified by comparing the serum proteomes of patients with and without nonbacterial prostatitis.

METHODS: All untreated samples were collected from subjects attending the Fangchenggang Area Male Health and Examination Survey (FAMHES). We profiled pooled serum samples from four carefully selected groups of patients (nā€‰=ā€‰10/group) representing the various categories of nonbacterial prostatitis (IIIa, IIIb, and IV) and matched healthy controls using a mass spectrometry-based 4-plex iTRAQ proteomic approach. More than 160 samples were validated by ELISA.

RESULTS: Overall, 69 proteins were identified. Among them, 42, 52, and 37 proteins were identified with differential expression in Category IIIa, IIIb, and IV prostatitis, respectively. The 19 common proteins were related to immunity and defense, ion binding, transport, and proteolysis. Two zinc-binding proteins, superoxide dismutase 3 (SOD3), and carbonic anhydrase I (CA1), were significantly higher in all types of prostatitis than in the control. A receiver operating characteristic curve estimated sensitivities of 50.4 and 68.1% and specificities of 92.1 and 83.8% for CA1 and SOD3, respectively, in detecting nonbacterial prostatitis. The serum CA1 concentration was inversely correlated to the zinc concentration in expressed-prostatic secretions.

CONCLUSIONS: Our findings suggest that SOD3 and CA1 are potential diagnostic markers of nonbacterial prostatitis, although further large-scale studies are required. The molecular profiles of nonbacterial prostatitis pathogenesis may lay a foundation for discovery of new therapies.

Written by:
Yang X, Li H, Zhang C, Lin Z, Zhang X, Zhang Y, Yu Y, Liu K, Li M, Zhang Y, Lv W, Xie Y, Lu Z, Wu C, Teng R, Lu S, He M, Mo Z.   Are you the author?
Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, China; Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China; J Craig Venter Institute, Rockville, Maryland; Department of Urology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China; Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China; Center for Reproductive Medicine, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China; Center for Reproductive Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China; Public Health of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China.

Reference: Prostate. 2015 May 22. Epub ahead of print.
doi: 10.1002/pros.23028


PubMed Abstract
PMID: 26010976

UroToday.com Prostatitis Section